BioNTech SE (VIE:BNTX)

Revenue Breakdown

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
COVID-19 Vaccine Revenue (Post-FY2023 Reporting)	1.83B	2.00B	2.43B
Out-Licensing Revenue	-	613.00M	-
Other Sales Revenue (Post-FY2023 Reporting)	209.20M	261.60M	319.00M
Revenue (Other)	389.30M	184.60M	140.60M
Revenue (Total)	2.43B	3.05B	2.89B

Data Source: Fiscal.ai Last updated: Jun 30, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 8, 2026

Data Sources Report a data error